

PRIOR AUTHORIZATION POLICY

- POLICY:** Cystic Fibrosis – Pulmozyme Prior Authorization Policy
- Pulmozyme® (dornase alfa inhalation solution – Genentech/Roche)

REVIEW DATE: 05/15/2024

OVERVIEW

Pulmozyme, a recombinant human deoxyribonuclease I, is indicated in conjunction with standard therapies for the management of patients with **cystic fibrosis** to improve pulmonary function.¹

Guidelines

According to Patient Registry data compiled by the Cystic Fibrosis Foundation (2022), Pulmozyme is used by the vast majority of patients with cystic fibrosis.² Guidelines from the Cystic Fibrosis Foundation (2007, updated in 2013) address the chronic use of medications for management of lung health in cystic fibrosis patients ≥ 6 years of age.^{3,4} These guidelines recommend Pulmozyme use for patients with cystic fibrosis regardless of disease severity to improve lung function and reduce exacerbations. Separate guidelines have addressed Pulmozyme use in younger patients.^{5,6} Although efficacy data are lacking in patients < 5 years of age, safety and tolerability have been established in patients as young as 3 months.^{1,6} Cystic Fibrosis Foundation guidelines for infants < 2 years of age (2009) and children between 2 and 5 years of age (2016) support Pulmozyme use in these populations based on individual circumstances.^{5,6}

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Pulmozyme. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Pulmozyme as well as the monitoring required for adverse events and long-term efficacy, approval requires Pulmozyme to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Pulmozyme is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Cystic Fibrosis.** Approve for 1 year if the medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.

05/15/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Pulmozyme is not recommended in the following situations:

1. **Asthma.** Mucus hypersecretion may be mediated by a variety of causes, including inflammation, irritation, stimulation, or mucus-producing tumors.⁷ However, efficacy of Pulmozyme is not established for conditions other than cystic fibrosis.¹⁰ In a pilot study of patients with severe acute asthma (n = 50), there was no significant difference in forced expiratory volume in 1 second (FEV₁) with Pulmozyme use vs. placebo.^{8,10}
3. **Bronchiectasis, Idiopathic.** A multicenter, double-blind, randomized, placebo-controlled 24-week trial (n = 349) examined the effect of Pulmozyme vs. placebo in patients with idiopathic bronchiectasis (i.e., bronchiectasis not related to cystic fibrosis).⁹ Patients in the Pulmozyme arm experienced worsened lung function and more frequent pulmonary exacerbations vs. placebo. The authors concluded that Pulmozyme should not be used in this population. Another small double-blind, placebo-controlled, Phase II trial (n = 14) examined Pulmozyme in adults with non-cystic fibrosis bronchiectasis. Pulmozyme failed to show any significant change in any of the outcome variables or in sputum transportability.^{10,11}
4. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Pulmozyme® inhalation solution [prescribing information]. South San Francisco, CA: Genentech/Roche; February 2024.
2. Cystic Fibrosis Foundation. Patient Registry: 2022 Annual Data Report. Available at: <https://www.cff.org/medical-professionals/patient-registry>. Accessed on May 2, 2024.
3. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. *Am J Respir Crit Care Med.* 2007;176:957-969.
4. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al, Pulmonary Clinical Practice Guidelines Committee. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. *Am J Respir Crit Care Med.* 2013;187(7):680-689.
5. Borowitz D, Robinson KA, Rosenfeld M, et al, Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr.* 2009;155(6 Suppl):S73-93.
6. Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. *Pediatrics.* 2016;137(4): e20151784.
7. Rubin BK. Aerosol medications for treatment of mucus clearance disorders. *Respiratory Care.* 2015;60(6):825-832.
8. Silverman RA, Foley F, Dalipi R, et al. The use of rhDNase in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study. *Respir Med.* 2012; 106(8):1096-1102.
9. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest.* 1998;113(5):1329-1334.
10. Tarrant BJ, Le Maitre C, Romero L, et al. Mucoactive agents for non-cystic fibrosis lung disease: a systematic review and meta-analysis. *Respirology.* 2017;22(6):1084-1092.
11. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, and Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. *Am J Respir Crit Care Med.* 1996;154:413-417.